Andy Pike
Impact in
-
- Peptidase Inhibition and Analysis
- Global Cancer Incidence and Screening
- Cancer Risks and Factors
-
- Multiple Myeloma Research and Treatments
Papers in
-
- Protein Degradation and Inhibitors 7
- Ubiquitin and proteasome pathways 5
- DNA Repair Mechanisms 3
- Protein purification and stability 2
- Oncology 8
- PARP inhibition in cancer therapy 4
- Peptidase Inhibition and Analysis 3
- Co-authors
- Beth Williamson (2 shared papers)Dermot F. McGinnity (2 shared papers)Scott Martin (2 shared papers)Stephanie Harlfinger (1 shared paper)Donna Shoupe (1 shared paper)Malcolm C. Pike (1 shared paper)Yuri R. Parisky (1 shared paper)Darcy Spicer (1 shared paper)
- Journals
- Drug Metabolism and Disposition (4 papers)Journal of Medicinal Chemistry (3 papers)Cancer Research (3 papers)MedChemComm (2 papers)Journal of Pharmaceutical Sciences (1 paper)
- Partner nations
- United KingdomUnited StatesSingapore
In The Last Decade
Andy Pike
23 papers receiving 432 citations
Peers
Comparison fields: 5 of 65
- Oncology 203
- Hematology 54
- Molecular Biology 250
- Cancer Research 43
- Pulmonary and Respiratory Medicine 78
Countries citing papers authored by Andy Pike
This map shows the geographic impact of Andy Pike's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andy Pike with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andy Pike more than expected).
Fields of papers citing papers by Andy Pike
This network shows the impact of papers produced by Andy Pike. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andy Pike. The network helps show where Andy Pike may publish in the future.
Co-authors
The 25 scholars most cited alongside Andy Pike, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 155 | |
| 2 | 1994 | 115 | |
| 3 | 2024 | 32 | |
| 4 | 2023 | 29 | |
| 5 | 2006 | 19 | |
| 6 | 2006 | 14 | |
| 7 | 2020 | 13 | |
| 8 | 1986 | 12 | |
| 9 | 2016 | 10 | |
| 10 | 2025 | 6 | |
| 11 | 2016 | 6 | |
| 12 | 2025 | 6 | |
| 13 | 2024 | 5 | |
| 14 | 2022 | 5 | |
| 15 | 2020 | 3 | |
| 16 | 2021 | 3 | |
| 17 | 2021 | 3 | |
| 18 | 2022 | 3 | |
| 19 | 1992 | 2 | |
| 20 | 2022 | 2 |
About Andy Pike
Andy Pike is a scholar working on Molecular Biology, Oncology, Organic Chemistry, Radiology, Nuclear Medicine and Imaging and Nephrology, having authored 24 papers that have together received 447 indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (7 papers), Ubiquitin and proteasome pathways (5 papers), PARP inhibition in cancer therapy (4 papers), DNA Repair Mechanisms (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Peptidase Inhibition and Analysis (3 papers), Quinazolinone synthesis and applications (2 papers) and Protein purification and stability (2 papers). The work is most often cited by research in Oncology (203 citations), Hematology (54 citations), Molecular Biology (250 citations), Cancer Research (43 citations) and Pulmonary and Respiratory Medicine (78 citations). Andy Pike has collaborated with scholars based in United Kingdom, United States and Singapore. Frequent co-authors include Beth Williamson, Dermot F. McGinnity, Scott Martin, Stephanie Harlfinger, Donna Shoupe, Malcolm C. Pike, Yuri R. Parisky, Darcy Spicer, John G. Pearce and Giske Ursin. Their work appears in journals such as Drug Metabolism and Disposition, Journal of Medicinal Chemistry, Cancer Research, MedChemComm and Journal of Pharmaceutical Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.